Pharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985).

New drug development in the United States, 1963 through 1984

Mattison, N., Trimble, A. G., & Lasagna, L. C. (1988) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1988.35 · Cited by 53

Drug innovation—what's slowing it down?

Steward, F., & Wibberley, G. (1980) · Nature · doi:10.1038/284118a0 · Cited by 44

The rate of development of new drugs in the United States, 1963 through 1975

Wardell, W. M., Hassar, M., & Anavekar, S. N. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1978242133 · Cited by 32

A survey of products licensed in the United Kingdom from 1971‐1981.

Griffin, J. L., & Diggle, G. E. (1981) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1981.tb01251.x · Cited by 27

The Measurement of Pharmaceutical Innovation

Wardell, W. M., & DiRaddo, J. (1980) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1980.tb01660.x · Cited by 21

Pharmaceuticals in seven nations

Chew, R., Smith, G. T., & Wells, N. E. J. (1985) · Monographs · Cited by 18

Trends in the development of new medicines by UK‐owned pharmaceutical companies (1964‐1980).

Prentis, R., & Walker, S. (1986) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1986.tb05219.x · Cited by 16

A survey of the first year of operation of the new procedure affecting the conduct of clinical trials in the United Kingdom.

Speirs, C., & Griffin, J. P. (1983) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1983.tb01545.x · Cited by 15

Is pharmaceutical innovation declining?: interpreting measures of pharmaceutical innovation and regulatory impact in the USA, 1950-1980.

Wardell, W. M., & Le, S. (1983) · PubMed · Cited by 10

The development of self-originated new drugs by Swiss pharmaceutical firms, 1960–1980

Mattison, N., Thomas, E., Trimble, A. G., & Wardell, W. M. (1984) · Regulatory Toxicology and Pharmacology · doi:10.1016/0273-2300(84)90038-2 · Cited by 10

Roles of Individual Human Cytochrome P450 Enzymes in Drug Metabolism

Guengerich, F. P. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001173 · Cited by 68

Validation of Early Human Dose Prediction: A Key Metric for Compound Progression in Drug Discovery

Page, K. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00840 · Cited by 63

Use of HμREL Human Coculture System for Prediction of Intrinsic Clearance and Metabolite Formation for Slowly Metabolized Compounds

Hultman, I., Vedin, C., Abrahamsson, A., Winiwarter, S., & Darnell, M. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00396 · Cited by 64

Impact of preformulation on drug development

Bharate, S. S., & Vishwakarma, R. A. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.783563 · Cited by 63

High-Throughput Prediction of Blood−Brain Partitioning: A Thermodynamic Approach

Keserű, G. M., & Molnár, L. M. (2000) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000043z · Cited by 62

Nano-extrusion: a One-Step Process for Manufacturing of Solid Nanoparticle Formulations Directly from the Liquid Phase

Khinast, J., Baumgartner, R., & Roblegg, E. (2013) · AAPS PharmSciTech · doi:10.1208/s12249-013-9946-0 · Cited by 61

Carbamazepine: a 'blind' assessment of CYP-associated metabolism and interactions in human liver-derivedin vitrosystems

Pelkonen, O., Myllynen, P. K., Taavitsainen, P., Boobis, A. R., Watts, P. S., Lake, B. G., Price, R. J., Renwick, A. B., Gómez‐Lechón, M. J., Castell, J. V., et al. (2001) · Xenobiotica · doi:10.1080/00498250110055479 · Cited by 61

Implications of polymorphic cytochrome p450-dependent drug metabolism for drug development.

Ingelman‐Sundberg, M. (2001) · PubMed · Cited by 61

Solid Dispersions : An Approach to Enhance the Bioavailability of Poorly Water-Soluble Drugs

Das, S. K. (2013) · International Journal of Pharmacology and Pharmaceutical Technology · doi:10.47893/ijppt.2013.1006 · Cited by 60

Defining “Innovativeness” in Drug Development: A Systematic Review

Kesselheim, A. S., Wang, B., & Avorn, J. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.115 · Cited by 59

Role of pharmacokinetics in the discovery and development of indinavir

Lin, J. H. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(99)00018-6 · Cited by 59

Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery

Stoner, C. L., Cleton, A., Johnson, K., Oh, D.-M., Hallak, H., Brodfuehrer, J., Surendran, N., & Han, H. (2003) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.09.006 · Cited by 59

Design of porous microparticles with single-micron size by novel spray freeze-drying technique using four-fluid nozzle

Niwa, T., Shimabara, H., Kondo, M., & Danjo, K. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.08.011 · Cited by 56

Agonists for the Adenosine A1Receptor with Tunable Residence Time. A Case for Nonribose 4-Amino-6-aryl-5-cyano-2-thiopyrimidines

Louvel, J., Guo, D. M., Agliardi, M., Mocking, T. A. M., Kars, R., Pham, T. P., Xia, L., de Vries, H., Brussee, J., Heitman, L. H., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401643m · Cited by 56

Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned

Choi, R., Hulverson, M. A., Huang, W., Vidadala, R. S. R., Whitman, G. R., Barrett, L. K., Schaefer, D. A., Betzer, D. P., Riggs, M. W., Doggett, J. S., et al. (2020) · International Journal for Parasitology · doi:10.1016/j.ijpara.2020.01.006 · Cited by 52

Compound Classification Using Image‐Based Cellular Phenotypes

Adams, C. L., Kutsyy, V., Coleman, D. A., Cong, G., Crompton, A. M., Elias, K. A., Oestreicher, D. R., Trautman, J. K., & Vaisberg, E. (2006) · Methods in Enzymology · doi:10.1016/s0076-6879(06)14024-0 · Cited by 51

Clinical attrition due to biased preclinical assessments of potential efficacy

Lindner, M. D. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.05.002 · Cited by 49

Validating ADME QSAR Models Using Marketed Drugs

Siramshetty, V. B., Williams, J., Nguyễn, Ð.-T., Neyra, J., Southall, N. T., Mathé, E. A., Xu, X., & Shah, P. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211017520 · Cited by 58

The use of in vitro cell culture models for mechanistic studies and as permeability screens for the blood–brain barrier in the pharmaceutical industry—Background and current status in the drug discovery process

Lundquist, S., & Renftel, M. (2002) · Vascular Pharmacology · doi:10.1016/s1537-1891(02)00203-3 · Cited by 54

Discovery of Innovative Therapeutics: Today’s Realities and Tomorrow’s Vision. 2. Pharma’s Challenges and Their Commitment to Innovation

Abou-Gharbia, M. A., & Childers, W. E. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401564r · Cited by 52

Guidelines for the experimental design of pharmacokinetic studies with nanomaterials in preclinical animal models

Valic, M. S., Halim, M., Schimmer, P., & Zheng, G. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.002 · Cited by 49

Organic anion transporting polypeptides: Pharmacology, toxicology, structure, and transport mechanisms.

Hagenbuch, B., Stieger, B., & Locher, K. (2024) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100023 · Cited by 49

In vitro methods to assess drug precipitation

Dai, W. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.03.040 · Cited by 49

ADME properties evaluation in drug discovery: in silico prediction of blood–brain partitioning

Zhu, L., Zhao, J., Zhang, Y., Zhou, W., Yin, L., Wang, Y., Fan, Y., Chen, Y., & Liu, H. (2018) · Molecular Diversity · doi:10.1007/s11030-018-9866-8 · Cited by 48

Cyclodextrin in drug delivery: Exploring scaffolds, properties, and cutting-edge applications

Singh, P., & Mahar, R. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124485 · Cited by 47

Approaches to higher-throughput pharmacokinetics (HTPK) in drug discovery

Watt, A. P., Morrison, D., & Evans, D. C. (2000) · Drug Discovery Today · doi:10.1016/s1359-6446(99)01434-8 · Cited by 47

Nitrendipine Nanocrystals: Its Preparation, Characterization, and In Vitro–In Vivo Evaluation

Quan, P., Xia, D., Piao, H., Piao, H., Shi, K., Jia, Y., & Cui, F. (2011) · AAPS PharmSciTech · doi:10.1208/s12249-011-9682-2 · Cited by 47

Monitoring drug–serum protein interactions for early ADME prediction through Surface Plasmon Resonance technology

Fabini, E., & Danielson, U. H. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.03.054 · Cited by 49

dendPoint: a web resource for dendrimer pharmacokinetics investigation and prediction

Kaminskas, L. M., Pires, D. E. V., & Ascher, D. B. (2019) · Scientific Reports · doi:10.1038/s41598-019-51789-3 · Cited by 46

Formulation and Evaluation of Liquisolid Compacts for Olmesartan Medoxomil

Prajapati, S. T., Bulchandani, H. H., Patel, D. M., Dumaniya, S. K., & Patel, C. N. (2013) · Journal of Drug Delivery · doi:10.1155/2013/870579 · Cited by 47

Preparation of itraconazole/HP-β-CD inclusion complexes using supercritical aerosol solvent extraction system and their dissolution characteristics

Lee, S., Jung, I.-I., Kim, J., Lim, G., & Ryu, J. (2007) · The Journal of Supercritical Fluids · doi:10.1016/j.supflu.2007.09.006 · Cited by 46

Executive (dys)function after stroke: special considerations for behavioral pharmacology

Povroznik, J. M., Ozga, J. E., Haar, C. V., & Engler-Chiurazzi, E. B. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000432 · Cited by 48

QSAR modeling of β-lactam binding to human serum proteins

Hall, L. M., Hall, L. H., & Kier, L. B. (2003) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1025309604656 · Cited by 45

Metabolism of the anthelmintic drug niclosamide by cytochrome P450 enzymes and UDP-glucuronosyltransferases: metabolite elucidation and main contributions from CYP1A2 and UGT1A1

Lu, D., Ma, Z., Zhang, T., Zhang, X., & Wu, B. (2015) · Xenobiotica · doi:10.3109/00498254.2015.1047812 · Cited by 44

An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant.

Andersson, T. B., Sjöberg, H., Hoffmann, K., Boobis, A. R., Watts, P. S., Edwards, R. J., Lake, B. G., Price, R. J., Renwick, A. B., Gómez-Lechón, M. J., et al. (2001) · PubMed · Cited by 44

Complementary new approaches enable repositioning of failed drug candidates

Tartaglia, L. A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.11.1295 · Cited by 44

Rapid Microbiologic and Pharmacologic Evaluation of Experimental Compounds against Mycobacterium tuberculosis

Gruppo, V., Johnson, C. M., Marietta, K. S., Scherman, H., Zink, E. E., Crick, D. C., Adams, L. B., Orme, I. M., & Lenaerts, A. J. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1245-1250.2006 · Cited by 44

Strategies for the design of nanoparticles: starting with long-circulating nanoparticles, from lab to clinic

Wang, R., Zhang, Z., Liu, B., Xue, J., Liu, F., Tang, T., Liu, W., Feng, F., & Qu, W. (2021) · Biomaterials Science · doi:10.1039/d0bm02221g · Cited by 46

Prediction of Total Drug Clearance in Humans Using Animal Data: Proposal of a Multimodal Learning Method Based on Deep Learning

Iwata, H., Matsuo, T., Mamada, H., Motomura, T., Matsushita, M., Fujiwara, T., Maeda, K., & D, K. H. M. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.01.020 · Cited by 42

Artificial neural network models for prediction of intestinal permeability of oligopeptides

Jung, E., Kim, J., Kim, M., Jung, D. H., Rhee, H., Shin, J., Choi, K., Kang, S., Kim, M.-K., Yun, C., et al. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-245 · Cited by 42

Early metabolism evaluation making traditional Chinese medicine effective and safe therapeutics

Liu, Y., & Yang, L. (2006) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.2006.b0099 · Cited by 43

pH-permeability profiles for drug substances: Experimental detection, comparison with human intestinal absorption and modelling

Oja, M., & Maran, U. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.07.014 · Cited by 41

New Quinoline–Urea–Benzothiazole Hybrids as Promising Antitubercular Agents: Synthesis, In Vitro Antitubercular Activity, Cytotoxicity Studies, and In Silico ADME Profiling

Moodley, R., Mashaba, C., Rakodi, G. H., Ncube, N. B., Maphoru, M. V., Balogun, M. O., Jordan, A., Warner, D. F., Khan, R. B., & Tukulula, M. (2022) · Pharmaceuticals · doi:10.3390/ph15050576 · Cited by 43

Clinical investigators as critical determinants in pharmaceutical innovation

Flowers, C. R., & Melmon, K. L. (1997) · Nature Medicine · doi:10.1038/nm0297-136 · Cited by 41

Improved early clinical development through human microdosing studies

Wilding, I. R., & Bell, J. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03509-9 · Cited by 40

Lipophilicity in trans-bilayer transport and subcellular pharmacokinetics

Baláž, Š. (2000) · Perspectives in Drug Discovery and Design · doi:10.1023/a:1008775707749 · Cited by 40

Microdialysis in Drug Discovery

Höcht, C., Opezzo, J. A. W., & Taira, C. A. (2004) · Current Drug Discovery Technologies · doi:10.2174/1570163043334848 · Cited by 39

Stable Knock-down of Efflux Transporters Leads to Reduced Glucuronidation in UGT1A1-Overexpressing HeLa Cells: The Evidence for Glucuronidation-Transport Interplay

Zhang, X., Dong, D., Wang, H., Ma, Z., Wang, Y., & Wu, B. (2015) · Molecular Pharmaceutics · doi:10.1021/mp5008019 · Cited by 38

Compound high-quality criteria: a new vision to guide the development of drugs, current situation

Mignani, S. M., Huber, S., Tomás, H., Rodrigues, J., & Majoral, J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.005 · Cited by 39

Self-nanoemulsifying drug delivery system of cefpodoxime proxetil containing tocopherol polyethylene glycol succinate

Bajaj, A., Rao, M. R. P., Khole, I., & Munjapara, G. (2012) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2012.683440 · Cited by 38

Synthesis, characterization, in vitro antimycobacterial and cytotoxicity evaluation, DFT calculations, molecular docking and ADME studies of new isomeric benzimidazole-1,2,3-triazole-quinoline hybrid mixtures

Nyoni, N. T. P., Ncube, N. B., Kubheka, M. X., Mkhwanazi, N. P., Senzani, S., Singh, T., & Tukulula, M. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106904 · Cited by 37

Design of Dry Nanosuspension with Highly Spontaneous Dispersible Characteristics to Develop Solubilized Formulation for Poorly Water-Soluble Drugs

Niwa, T., Miura, S., & Danjo, K. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0465-y · Cited by 37

Design of Tunable Multicomponent Polymers as Modular Vehicles To Solubilize Highly Lipophilic Drugs

Ting, J., Navale, T. S., Bates, F. S., & Reineke, T. M. (2014) · Macromolecules · doi:10.1021/ma501839s · Cited by 37

Effect of size and processing method on the cytotoxicity of realgar nanoparticles in cancer cell lines

Zhao, W., Zhao, W., Lu, Yuan, Y., Liu, Yang, Zeng, Wang, & Hong (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s21373 · Cited by 36

Cancer risk of petrochemical workers exposed to airborne PAHs in industrial Lanzhou City, China

Wang, L., Zhao, Y., Xianying, L., Huang, T., Wang, Y., Gao, H. R., & Ma, J. (2015) · Environmental Science and Pollution Research · doi:10.1007/s11356-015-5203-2 · Cited by 35

The continuing evolution of the drug discovery process in the pharmaceutical industry

Ratti, E., & Trist, D. G. (2001) · Il Farmaco · doi:10.1016/s0014-827x(01)01019-9 · Cited by 35

Density functional and molecular docking studies towards investigating the role of single-wall carbon nanotubes as nanocarrier for loading and delivery of pyrazinamide antitubercular drug onto pncA protein

Saikia, N., Rajkhowa, S., & Deka, R. C. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-013-9638-6 · Cited by 36

The Development, Characterization, and Application of an OATP1B1 Inhibition Assay in Drug Discovery

Soars, M. G., Barton, P., Ismair, M. G., Jupp, R., & Riley, R. J. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042382 · Cited by 34

Structure-kinetics relationships of Capadenoson derivatives as adenosine A 1 receptor agonists

Louvel, J., Guo, D. M., Soethoudt, M., Mocking, T. A. M., Lenselink, E. B., Mulder‐Krieger, T., Heitman, L. H., & IJzerman, A. P. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.07.023 · Cited by 34

Design of drugs through a consideration of drug metabolism and pharmacokinetics

Smith, D. A. (1994) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03188921 · Cited by 34

Physiologically Based Pharmacokinetic Modeling in Lead Optimization. 1. Evaluation and Adaptation of GastroPlus To Predict Bioavailability of Medchem Series

Daga, P. R., Bolger, M. B., Haworth, I. S., Clark, R. D., & Martin, E. J. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00972 · Cited by 33

In Silico ADME Modeling 3: Computational Models to Predict Human Intestinal Absorption Using Sphere Exclusion and kNN QSAR Methods

Gunturi, S. B., & Ramamurthi, N. (2007) · QSAR & Combinatorial Science · doi:10.1002/qsar.200630094 · Cited by 33

Characterization of hepatic drug-metabolizing activities of Bama miniature pigs (Sus scrofa domestica): comparison with human enzyme analogs.

Li, J., Liu, Y., Zhang, J.-W., Hong Kui, W. E. I., & Yang, L. (2006) · PubMed · Cited by 33

ADME properties evaluation in drug discovery: Prediction of plasma protein binding using NSGA-II combining PLS and consensus modeling

Wang, N., Deng, Z., Huang, C., Dong, J. N., Zhu, M.-F., Yao, Z., Chen, A. F., Lü, A., Mi, Q., & Cao, D. (2017) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/j.chemolab.2017.09.005 · Cited by 32

Importance of tacit knowledge in incremental innovation

Okuyama, R. (2017) · Journal of strategy and management · doi:10.1108/jsma-02-2016-0016 · Cited by 31

Induction of Apoptosis and Down-Regulation of Bcl-XL in Cancer Cells by a Novel Small Molecule, 2[ [3-(2,3-Dichlorophenoxy)propyl]amino]ethanol

Wu, S., Zhu, H., Gu, J. H., Zhang, L., Teraishi, F., Davis, J. J., Jacob, D., & Fang, B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2790 · Cited by 31

Drug Delivery Systems: Study of Inclusion Complex Formation between Methylxanthines and Cyclodextrins and Their Thermodynamic and Transport Properties

Santos, C. I. A. V., Ribeiro, A. C. F., & Esteso, M. A. (2019) · Biomolecules · doi:10.3390/biom9050196 · Cited by 31

Selection of excipient, solvent and packaging to optimize the performance of spray-dried formulations: case example fenofibrate

Hugo, M., Kunath, K., & Dressman, J. (2012) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2012.685176 · Cited by 31

Role of metabolism and pharmacokinetic studies in the discovery of new drugs—present and future perspectives

Humphrey, M., & Smith, D. A. (1992) · Xenobiotica · doi:10.3109/00498259209053137 · Cited by 30

The Influence of Cosolvent on the Complexation of HP-β-cyclodextrins with Oleanolic Acid and Ursolic Acid

Li, R., Quan, P., Liu, D., Wei, F., Zhang, Q., & Xu, Q. (2009) · AAPS PharmSciTech · doi:10.1208/s12249-009-9317-z · Cited by 29

Saffron carotenoids (crocin and crocetin) binding to human serum albumin as investigated by different spectroscopic methods and molecular docking

Jafarisani, M., Bathaie, S. Z., & Mousavi, M. F. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1331865 · Cited by 29

Commercializing Successful Biomedical Technologies: Basic Principles for the Development of Drugs, Diagnostics and Devices

Mehta, S. S. (2008) · Cited by 29

A New Approach for β-cyclodextrin Conjugated Drug Delivery System in Cancer Therapy

Kumar, P. V., & Sheng, T. M. (2021) · Current Drug Delivery · doi:10.2174/1567201818666211006103452 · Cited by 28

Web resources for drug toxicity

Wolfgang, G. H. I., & Johnson, D. E. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00022-7 · Cited by 28

Effect of diverse datasets on the predictive capability of ADME models in drug discovery

Grass, G. M., & Sinko, P. J. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)00150-7 · Cited by 28

Cyclic Peptide Therapeutic Agents Discovery: Computational and Artificial Intelligence-Driven Strategies

Lin, K., Zhang, C., Bai, R., & Duan, H. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00712 · Cited by 30

Drug nanoparticles by emulsion-freeze-drying via the employment of branched block copolymer nanoparticles

Wais, U., Jackson, A. W., Zuo, Y., Xiang, Y., He, T., & Zhang, H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.022 · Cited by 27

Understanding the Role of Sodium Lauryl Sulfate on the Biorelevant Solubility of a Combination of Poorly Water-Soluble Drugs Using High Throughput Experimentation and Mechanistic Absorption Modeling

Bahr, M., Modi, D., Patel, S., Campbell, G. A., & Stockdale, G. (2019) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps30347 · Cited by 26

Relationship between immobilized artificial membrane chromatographic retention and human oral absorption of structurally diverse drugs

Kotecha, J., Shah, S. A., Rathod, I. S., & Subbaiah, G. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.10.010 · Cited by 26

Computational modeling of P450s for toxicity prediction

Mishra, N. K. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.611501 · Cited by 26

Results of molecular docking as descriptors to predict human serum albumin binding affinity

Chen, L., & Chen, X. (2011) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2011.11.003 · Cited by 25

Applications of machine learning and computational intelligence to drug discovery and development

Hecht, D. (2010) · Drug Development Research · doi:10.1002/ddr.20402 · Cited by 24

Multi-scale analysis of amorphous solid dispersions prepared by freeze drying of ibuprofen loaded acrylic polymer nanoparticles

Hassouna, F., Dahab, M. A. E., Fulem, M., Haiek, A. D. L., Laachachi, A., Kopecký, D., & Šoóš, M. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101182 · Cited by 24

Statistical learning approach for predicting specific pharmacodynamic, pharmacokinetic, or toxicological properties of pharmaceutical agents

Li, H., Yap, C. W., Xue, Y. W., Li, Z. R., Ung, C. Y., Han, L., & Chen, Y. (2005) · Drug Development Research · doi:10.1002/ddr.20044 · Cited by 24

Evaluation of an integrated in vitro–in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability

Cai, H., Stoner, C. L., Reddy, A., Freiwald, S., Smith, D., Winters, R. T., Stankovic, C. J., & Surendran, N. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.11.002 · Cited by 24

New Approaches to the Use of Pharmacokinetics in Toxicology and Drug Development

Campbell, D. B., & Ings, R. M. J. (1988) · Human Toxicology · doi:10.1177/096032718800700515 · Cited by 24

In SilicoADME/Tox Predictions

Lagorce, D., Reynès, C., Camproux, A., Miteva, M. A., Spérandio, O., & Villoutreix, B. O. (2010) · Wiley eBooks · doi:10.1002/9780470915110.ch2 · Cited by 25

Drug Discovery in Africa

Chibale, K., Masimirembwa, C. M., & Davies-Coleman, M. (2012) · Springer eBooks · doi:10.1007/978-3-642-28175-4 · Cited by 25

Artificial neural network approach for predicting blood brain barrier permeability based on a group contribution method

Wu, Z., Xian, Z., Ma, W., Liu, Q., Huang, X., Xiong, B., He, S., & Zhang, W. (2021) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2021.105943 · Cited by 25

Enhancement of Drug Solubility in Supramolecular and Colloidal Systems

Süle, A., Szente, L., & Csempesz, F. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21437 · Cited by 23

Do Drug Metabolism and Pharmacokinetic Departments Make Any Contribution to Drug Discovery?

Smith, D. A., Schmid, E. F., & Jones, B. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241130-00001 · Cited by 23

Computational evaluation of some indenopyrazole derivatives as anticancer compounds; application of QSAR and docking methodologies

Shahlaei, M., Fassihi, A., Saghaie, L., Arkan, E., Madadkar‐Sobhani, A., & Pourhossein, A. (2011) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2011.618991 · Cited by 22

Novel Spray Freeze-Drying Technique Using Four-Fluid Nozzle-Development of Organic Solvent System to Expand Its Application to Poorly Water Soluble Drugs

Niwa, T., Shimabara, H., & Danjo, K. (2010) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.58.195 · Cited by 22

Studies of intestinal drug transport using an in silico epithelio-mimetic device

Liu, Y., & Hunt, C. A. (2005) · Biosystems · doi:10.1016/j.biosystems.2005.06.008 · Cited by 22

Are single-dose toxicology studies in animals adequate to support single doses of a new drug in humans?

Monro, A. M., & Mehta, D. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)80002-6 · Cited by 22

The integrative bioinformatics approaches to predict the xanthohumol as anti-breast cancer molecule: Targeting cancer cells signaling PI3K and AKT kinase pathway

Gupta, K. K., Sharma, K. K., Chandra, H., Panwar, H., Bhardwaj, N., Altwaijry, N., Alsfouk, A. A., Dlamini, Z., Afzal, O., Altamimi, A. S. A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.950835 · Cited by 20

Plasma protein binding prediction focusing on residue-level features and circularity of cyclic peptides by deep learning

Li, J., Yanagisawa, K., Yoshikawa, Y., Ohue, M., & Akiyama, Y. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab726 · Cited by 21

Machine learning algorithms for the prediction of hERG and CYP450 binding in drug development

Klon, A. E. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.489550 · Cited by 21

Toward an integrated human clearance prediction strategy that minimizes animal use

Beaumont, K. C., Gardner, I. B., Chapman, K. L., Hall, M., & Rowland, M. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22635 · Cited by 21

Bioavailability Enhancement of Poorly Water Soluble and Weakly Acidic New Chemical Entity with 2-Hydroxy Propyl-β-Cyclodextrin: Selection of Meglumine, a Polyhydroxy Base, as a Novel Ternary Component

Basavaraj, S. N., Sihorkar, V., Kumar, T. R., Sundaramurthi, P., Srinivas, N. R., Venkatesh, P., Mullangi, R., & Singh, S. K. (2006) · Pharmaceutical Development and Technology · doi:10.1080/10837450600770577 · Cited by 21

Trends in the development of new medicines by UK‐owned pharmaceutical companies (1964‐1980).

Prentis, R., & Walker, S. (1986) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1986.tb05219.x · Cited by 16

Novel medicines marketed in the UK (1960‐87).

Lis, Y., & Walker, S. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb05435.x · Cited by 13

New drug development by United States pharmaceutical firms: With analyses of trends in the acquisition and origin of drug candidates, 1963-1979*

Wardell, W. M., May, M. S., & Trimble, A. G. (1982) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1982.181 · Cited by 20

Development of new drugs originated and acquired by United States–owned pharmaceutical firms, 1963-1976*

Wardell, W. M., DiRaddo, J., & Trimble, A. G. (1980) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1980.160 · Cited by 16

New drug development during and after a period of regulatory change: Clinical research activity of major united states pharmacxeutical firms, 1958 to 1979

May, M. S., Wardell, W. M., & Lasagna, L. C. (1983) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1983.95 · Cited by 12